SEC Form 4 · accession 0001209191-15-010573
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas W. Pagan
Officer — Chief Financial Officer
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 9:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | $24.07 | Feb 4, 2015 | A | 35,000 | A | — | — | Common Stock | 35,000 | 35,000 | D |
| Stock Option (right to buy)F3,F4 | $24.07 | Feb 4, 2015 | A | 160,000 | A | — | Feb 3, 2025 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Company's Common Stock.
- F2The restricted stock units will vest in full (100%) on the three year anniversary of the date of grant, subject to continued service with the Company.
- F3The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
- F4The shares shall vest as follows: 40,000 shares (25%) shall vest on December 18, 2015; and the remaining 120,000 (75%) shares shall vest in monthly installments of 3,333 shares (1/36th) on a monthly basis thereafter.